Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study
暂无分享,去创建一个
L. Staudt | A. Rosenwald | W. Chan | T. Greiner | D. Weisenburger | W. Wilson | J. Vose | R. Gascoyne | P. Gaulard | E. Campo | L. Rimsza | E. Jaffe | J. Delabie | M. Piris | R. Braziel | M. Sánchez-Beato | W. Rehrauer | K. Young | K. Leroy | C. Haioun | J. Eickhoff | J. Malter | M. Møller | T. Oberley | G. Colleoni | B. Kahl | James Z. Huang | F. Kerbauy | A. H. Young
[1] L. Staudt,et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. , 2007, Blood.
[2] E. Campo,et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Blandino,et al. Mutant p53 proteins: Between loss and gain of function , 2007, Head & neck.
[4] M. Hollstein,et al. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.
[5] T. Greiner. Enhanced Detection of TP53 Mutations Using a GC-clamp in Denaturing High Performance Liquid Chromatography , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[6] W. Wilson,et al. Drug resistance in diffuse large B-cell lymphoma. , 2006, Seminars in hematology.
[7] T. Naoe,et al. Promoter Hypermethylation of the DNA-Repair Gene O6-Methylguanine—DNA Methyltransferase and p53 Mutation in Diffuse Large B-cell Lymphoma , 2006, International journal of hematology.
[8] A. Levine,et al. The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.
[9] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[10] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] M. Shipp. New concepts in treatment approaches and prognostic factors in aggressive NHL. , 2006, Clinical advances in hematology & oncology : H&O.
[12] V. Rotter,et al. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 , 2006, Oncogene.
[13] P. Hall,et al. Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.
[14] D. Kerr,et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T. Soussi,et al. p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.
[16] G. Lozano,et al. What have animal models taught us about the p53 pathway? , 2005, The Journal of pathology.
[17] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[18] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[19] J. Kobarg,et al. Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature , 2004, Leukemia & lymphoma.
[20] R. Mariani-Costantini,et al. TP53 in gastric cancer: Mutations in the L3 loop and LSH motif DNA‐binding domains of TP53 predict poor outcome , 2004, Journal of cellular physiology.
[21] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[22] David V Glidden,et al. Modelling clustered survival data from multicentre clinical trials , 2004, Statistics in medicine.
[23] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[24] L. Staudt,et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.
[25] Brian J. Smith,et al. The impact of p53 protein core domain structural alteration on ovarian cancer survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] A. Inga,et al. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[27] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Arsène,et al. Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). , 2003, Mutagenesis.
[29] V. Rotter,et al. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.
[30] B. Cheson. Hematologic malignancies: new developments and future treatments. , 2002, Seminars in oncology.
[31] P. Gaulard,et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[33] M. Oren,et al. Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities* , 2002, The Journal of Biological Chemistry.
[34] A. Ganser,et al. Tumor suppressor genes in normal and malignant hematopoiesis , 2002, Oncogene.
[35] S. Barrans,et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.
[36] Alison L. Cuff,et al. Integrating mutation data and structural analysis of the TP53 tumor‐suppressor protein , 2002, Human mutation.
[37] M. Olivier,et al. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. , 2001, Seminars in cancer biology.
[38] A. Sánchez-Aguilera,et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. , 2001, The American journal of pathology.
[39] P. Slootweg,et al. Gain-of-function mutations in the tumor suppressor gene p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[41] R. Kanamaru,et al. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. , 1999, Anti-cancer drug design.
[42] D. Louis,et al. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma , 1999, Leukemia.
[43] A. Levine,et al. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.
[44] J. Cleveland,et al. Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.
[45] S. Deb,et al. `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.
[46] F. Bosch,et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.
[47] P. Koduru,et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. , 1997, Blood.
[48] J N Weinstein,et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.
[49] C. Preudhomme,et al. THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIES , 1997, British journal of haematology.
[50] H. Saito,et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[51] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[52] S. Deb,et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53 , 1996, Molecular and cellular biology.
[53] H. Werner,et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[54] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[55] M. Kaneuchi,et al. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. , 1996, Oncogene.
[56] W. Chan,et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.
[57] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[58] E. Hovig,et al. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.
[59] D. Housman,et al. p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.
[60] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[61] W. Kolch,et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.
[62] D. Longo,et al. p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.
[63] E. Cesarman,et al. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. , 1993, The American journal of pathology.
[64] P. Sehgal,et al. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. , 1993, The Journal of biological chemistry.
[65] A. Levine,et al. Gain of function mutations in p53 , 1993, Nature Genetics.
[66] M. Subler,et al. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.
[67] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[68] K. Husgafvel‐Pursiainen,et al. Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing. , 2006, Cancer detection and prevention.
[69] M. Scian,et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. , 2005, Molecular and cellular biology.
[70] L. Staudt,et al. The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.
[71] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[72] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[73] A. Flahault,et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] A. Børresen-Dale,et al. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[76] C. Bellamy,et al. p53 and apoptosis. , 1997, British medical bulletin.
[77] T. Soussi,et al. The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. , 1996, Molecular medicine today.
[78] D.,et al. Regression Models and Life-Tables , 2022 .